Pfizer Sues Apotex to Block Generic Versions of Chantix Pills

Pfizer said Apotex’s proposed generic version of Chantix infringes two patents for the smoking-cessation tablets.

• Pfizer is seeking court order blocking copies until patents have expired and cash compensation if copies are made before then, according to complaint filed Thursday in federal court in Wilmington, Delaware
  • Patents expire in November 2022 and February 2023: FDA Orange Book
• First and only FDA-approved generic version of Chantix in the U.S. was launched Sept. 22 by Endo
• Pfizer in September 2020 settled a suit against Viwit over three Chantix patents, including the two at issue in the suit against Apotex
• Chantix had ...